Friday, 9 October 2015

13:45 - 14:00     Opening Remarks – Welcome                       Salle Erasme
                          Thomas F BAUMERT and François-Loïc COSSET

14:00 - 15:30     Session 1A: Clinical Challenges
                          Session chairs: Heiner WEDEMEYER & Lorne TYRRELL

14:00 - 14:15     Primer clinical challenges:
                          Jean-Michel PAWLOTSKY, University Paris-Est Créteil, Paris, France

14:15 - 15:30 Session 1A oral abstracts

14:15 - 14:30 Precision medicine for hepatitis C O1.01
  Thomas O’BRIEN, Shyam KOTTILIL, Jordan FELD, Ruth PFEIFFER  
14:30 - 14:45 HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir O1.02
  Harel DAHARI, Laetitia CANINI, Frederik GRAW, Susan UPRICHARD, Evaldo ARAU´JO, Guillaume PENARANDA, Emilie COQUET, Aurelie RISO, Christophe RENOU, Marc BOURLIERE, Scott COTLER, Philippe HALFON  
14:45 - 15:00 Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors +/- ribavirin is effective in genotypes 1 and 3 O1.03
  Graham FOSTER, John McLAUCHLAN, Will IRVING, Michelle CHEUNG, Ben HUDSON, Suman VERMA, Kosh AGARWAL  
15:00 - 15:15 Resistance and fitness of genotype 1 - 6 hepatitis C virus escape variants selected under protease inhibitor treatment in vitro O1.04
  Stéphanie BN SERRE, Sanne B JENSEN, Daryl G HUMES, Santseharay RAMIREZ, Yi-Ping LI, Lubna GHANEM, Jens BUKH, Judith M GOTTWEIN  
15:15 - 15:30 Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with Sofosbuvir combination therapies O1.05
  Miguel MALESPIN, Susan UPRICHARD, Alan PERELSON, Harel DAHARI, Scott COTLER  

 

15:30 - 16:00     Refreshment Break                                        Galerie de Marbre

16:00 - 17:45     Session 1B: Clinical Challenges
                          Session chairs: Christoph NEUMANN-HAEFELIN & Andrea COX

16:00 – 16:30 Plenary lecture: Brigitte AUTRAN

Brigitte AutranAnti-HCV immunity and immunopathology in HIV-HCV co-infection
Brigitte AUTRAN, MD, PhD, Professor of Immunology, Pitié-Salpêtrière University Hospital, Pierre and Marie Curie University, Paris, France

Prof. Autran’s research has led to key discoveries in the field of Human Immunodeficiency Virus (HIV) infection immunology and in the area of vaccine immunology. Major contributions in the field of HIV include the first demonstrations of: Immune system defenses against HIV, with the first description of cytotoxic T lymphocytes specific for HIV (Nature, 1987). This was followed by numerous contributions on the specificities, compartmentalization and dynamics of cytotoxic T lymphocytes directed against HIV and its variants, providing the rationale for HIV vaccine development research. Restoration of the immune system: with the first report of restoration of the immune system with the new, at the time, anti-retroviral therapies (Science 1997) describing recovery of memory and naïve CD4 T cells, restoration of memory T cell responses to opportunistic pathogens but not to HIV itself, thus opening a new era in the immunology of AIDS. Development of therapeutic vaccines and immune-based interventions in HIV-infection. Prof. Autran has developed international programs on therapeutic vaccines and new immune-based therapeutic strategies to accelerate CD4 T cell reconstitution, restore immunity to HIV and to control HIV disease (Nat. Rev. Immun., 2003, 2012; Science, 2000, 2004, 2009, Immunol. Rev. 2013). She also acts as an expert for vaccines at the French Ministry of Health and is a member of the WHO Global Advisory Committee on Vaccine Safety. She coordinates the AVIESAN-IMMI Consortium of Research on Vaccines (CoReVac).

 

16:00 - 17:45 Session 1B oral abstracts

16:30 - 16:45 HCV quasispecies evolution during pregnancy highlights the complexity of the mechanisms involved in mother-to-child HCV transmission O1.06
  Ariane LAROUCHE, Armelle LE CAMPION, Sebastien FAUTEUX-DANIEL, Jonathan BOULAIS, Marc BOUCHER, Normand LAPOINTE, Mel KRAJDEN, Deborah MONEY, Hugo SOUDEYNS  
16:45 - 17:00 Persistence of HCV dominant variants after liver transplantation in cholestatic hepatitis C patients O1.07
  Martina GAMBATO, Josep GREGORI,  Josep QUER, Noelia CARO-PéREZ, Patricia GONZALEZ, Damir GARCIA-CEHIC, Juan I ESTEBAN, Gonzalo CRESPO, Miquel NAVASA, Xavier FORNS, Sofia PEREZ-DEL-PULGAR  
17:00 - 17:15 A broadly neutralizing monoclonal antibody targeting hepatitis C virus prevents viral infection in vitro and in uPA/SCID mice with humanized liver O1.08
  Ahmed Atef MESALAM, Isabelle DESOMBERE, Richard URBANOWICZ, Daniel X JOHANSSON, Koen VERCAUTEREN, Ali FARHOUDI, Freya VAN HOUTTE, Lieven VERHOYE, Karin E WEENING, Mats PERSSON, Jonathan BALL, Geert LEROUX-ROELS, Philip MEULEMAN  
17:15 - 17:30 Humanization of a therapeutic claudin-1-specific antibody for cure of hepatitis C virus infection O1.09
  Rajiv G TAWAR, Che C COLPITTS, Laurent MAILLY, Christine THUMANN, Fei XIAO, Laura HEYDMANN, Sarah C DURAND, Mirjam B ZEISEL, Thomas F BAUMERT  
17:30 - 17:45 Effective prevention of direct-acting antiviral-resistant hepatitis C virus by combination with LNA-anti-miR-122 therapy in cell culture O1.10
  Fanwei LIU, Tetsuro SHIMAKAMI, Kazuhisa MURAI, Takayuki SHIRASAKI, Masaya FUNAKI, Masao HONDA, Hong TANG, Seishi MURAKAMI, Shuichi KANEKO  

 

18:00 - 20:00     Welcome Reception                                       Galerie de Marbre